Jeremiah Johnson, executive director of PrEP4All, an organization committed to HIV prevention and care, talks about the importance of preexposure anaphylaxis and why he’s hesitant to jump on the ...

In this interview, Sarah Morris, chief product officer of Audere, explains why they chose to focus on women and young girls and how they have tailored their program to reach them. There are ...

Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing ...

The FDA approved Anzupgo (delgocitinib) cream today as the first and only treatment specifically for adults with moderate-to-severe chronic hand eczema (CHE) in the United States. Chronic hand eczema ...

The FDA has accepted the resubmitted BLA for tabelecleucel (tab-cel), intended for the treatment of Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD).

A scleroderma patient in a Sylvester Comprehensive Cancer Center trial was recently successfully treated with CAR T-cell lymphoma therapy, in what researchers are calling an “immunological reset.” ...

Panelists discuss how autoantibody testing has high diagnostic accuracy with nearly 100% conversion to hyperglycemia when two or more antibodies are present, though timing of testing is crucial and ...

Employers increasingly shift health benefit costs to workers in 2026, while prioritizing mental health and innovative affordability strategies.

Audere is closing gaps in HIV care and education with the help of Aimee, their artificial intelligence companion designed to reach women and young girls in South Africa, according to Sarah Morris, CPO ...

The Vision Center at Children’s Hospital Los Angeles is developing a protocol for a phase 1 clinical trial for the first gene therapy for boys with blue cone monochromacy, which impairs color vision ...

Replimune's RP1 treatment for advanced melanoma faces FDA rejection due to trial design issues, despite promising results from the IGNYTE trial.

Samsung Bioepis released its Third Quarter 2025 United States Biosimilar Market Report today, providing an insight into industry pricing trends, dynamics and the Most-Favored-Nation (MFN) policy, ...